An investigational treatment for amyotrophic lateral sclerosis (ALS), SBT-272 was found to sustainably reach different brain regions, and to protect mitochondria — a cell’s energy source — from TDP-43 toxic aggregates in a mouse model of the disease. “We are excited about the promise of SBT-272 as a potential therapeutic…

Early trials in healthy adults supported the safety and tolerability of two potential oral therapies for amyotrophic lateral sclerosis (ALS) — DNL343 to prevent the cellular stress that can promote toxic protein granules, and DNL788 to block a protein linked to brain inflammation — Denali Therapeutics reported. A Phase…

An imaging agent developed by Ashvattha Therapeutics can accurately detect brain inflammation caused by microglia, immune cells that play a key role in neurological diseases such as amyotrophic lateral sclerosis (ALS), a mouse study reported. The company is planning to initiate a Phase 1/2 clinical trial in ALS…

Simultaneous injections of mesenchymal stem cells (MSCs) into the blood and spinal canal were found to delay disease progression in people with amyotrophic lateral sclerosis (ALS) in a small clinical trial. “Our results demonstrated that the IT [intrathecal, or into-the-spine] and IV transplantation of [MSCs] in ALS patients…

A five-year National Institutes of Health (NIH) grant worth $2.4 million will support an Emory University researcher’s use of artificial intelligence (AI) to accurately and quickly — in real time — decode the electrical signals sent by the brain to control movement. Its ultimate goal is to find ways to “reconnect” the…

Dimethyl fumarate or DMF — an oral therapy approved for multiple sclerosis (MS) — was well-tolerated among adults with amyotrophic lateral sclerosis (ALS) but failed to significantly slow disease progression or to improve survival and quality of life in these patients, according to data from a Phase 2…

Expansion Therapeutics has raised $80 million in funding to support the development of its small molecule RNA platform, called SMiRNA, for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Series B financing will help the drug development company use its platform to discover small molecules targeting RNA…

Cytokinetics is accepting applications from advocacy groups working in cardiovascular and neuromuscular diseases, including amyotrophic lateral sclerosis (ALS), for grants worth $20,000 each that will help them expand their communications and community engagement. In total, five Cytokinetics Communications Fellowship Grants will be awarded winning organizations. The deadline for applications…

The ALS Association has launched a new diagnostic guide — called thinkALS — to aid neurologists in more quickly suspecting and diagnosing amyotrophic lateral sclerosis (ALS) at its early stages. Early diagnosis will allow patients to join clinical trials, and to access treatments and care at disease stages where there’s…

Bionews Insights is launching a survey, in collaboration with ALS News Today, with the goal of understanding how different aspects of this disease affect an individual’s quality of life. The survey, which is expected to take about 15 minutes to complete, opens with WHOQOL-100, a set of questions developed by…